Welcome to our dedicated page for Kintara Therapeutics news (Ticker: KTRA), a resource for investors and traders seeking the latest updates and insights on Kintara Therapeutics stock.
Kintara Therapeutics, Inc. (Nasdaq: KTRA) generated frequent news as a biopharmaceutical company focused on developing new solid tumor cancer therapies and as the vehicle for a significant reverse merger with TuHURA Biosciences, Inc. Company press releases describe Kintara as located in San Diego, California and dedicated to novel cancer therapies for patients with unmet medical needs, with a lead program centered on REM-001 Therapy for cutaneous metastatic breast cancer (CMBC).
The KTRA news flow prominently features updates on REM-001 Therapy, including details of an open-label CMBC study, prior Phase 2/3 clinical experience, and the role of a Small Business Innovation Research grant from the National Institutes of Health in supporting study costs. These items provide context on the company’s proprietary late-stage photodynamic therapy platform, which combines a laser light source, a light delivery device, and the REM-001 drug product.
Another major theme in Kintara’s news coverage is its merger with TuHURA Biosciences, Inc. Articles outline the definitive merger agreement, stockholder meetings, voting instructions, and the strategic rationale for combining Kintara’s oncology assets with TuHURA’s Phase 3 registration-stage immuno-oncology programs. Releases discuss the expected ownership structure of the combined company, the planned corporate name change to TuHURA Biosciences, Inc., and the transition of trading to the Nasdaq Capital Market under the symbol HURA.
News items also detail corporate actions tied to the merger, including the approval and implementation of a 1-for-35 reverse stock split and the establishment of Contingent Value Rights (CVRs) to provide potential additional share consideration to Kintara stockholders upon achievement of specified REM-001 study milestones. Additional coverage includes reminders to stockholders to vote on key proposals, adjournments and reconvening of special meetings, and fiscal year financial results accompanied by corporate updates.
For readers following KTRA historically, this news archive offers insight into Kintara’s oncology development efforts, its financial and strategic decisions, and the sequence of events that led to the transformation of the Kintara listing into TuHURA Biosciences, Inc. under the HURA ticker. Regular review of these releases helps clarify how the company’s clinical programs and corporate structure evolved over time.
Kintara Therapeutics (Nasdaq: KTRA) has paused its REM-001 program targeting Cutaneous Metastatic Breast Cancer (CMBC) to conserve approximately $3 million through 2023. This decision enables funding for the ongoing VAL-083 international registrational study for glioblastoma. Despite the pause, the company aims to explore future funding options, including grants. Kintara continues to anticipate announcing top-line data for VAL-083 from the GBM AGILE study by the end of 2023, highlighting its commitment to addressing unmet medical needs in oncology.
Kintara Therapeutics (KTRA) reported its financial results for the fiscal year ending June 30, 2022, with a net loss of $22.7 million, or $0.52 per share, compared to a loss of $38.3 million, or $1.60 per share in the previous year. Cash and cash equivalents stood at approximately $11.8 million. Key developments include FDA Fast Track Designation for VAL-083 and initiation of a 15-patient study for REM-001 PDT. The company secured a $20 million equity facility with Lincoln Park Capital. Kintara aims to enhance its clinical programs and plans to start patient enrollment for the CMBC study by the end of September 2022.
Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company, announced acceptance of three posters for data presentation at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting from November 16-20 in Tampa, Florida. The studies focus on VAL-083's application in various cancers, including a Phase 2 study in glioblastoma multiforme (GBM) and reports on recurrent ependymoma and glioblastoma treatments. Kintara’s VAL-083 and REM-001 therapies aim to address unmet medical needs in cancer treatment.
Kintara Therapeutics (KTRA) announced receiving a Study May Proceed letter from the FDA to initiate a study on REM-001 Photodynamic Therapy for Cutaneous Metastatic Breast Cancer (CMBC). The study aims to enroll 15 patients and assess tumor response using 3D digital photography. Kintara's CEO highlighted this as a significant milestone, aligning with the company's strategy to address unmet medical needs in CMBC and other cutaneous cancers. Kintara is also advancing its VAL-083 program for glioblastoma, emphasizing its commitment to cancer therapy innovation.
Kintara Therapeutics (Nasdaq: KTRA) announced an equity purchase agreement with Lincoln Park Capital for up to $20 million. This agreement allows Kintara to sell shares at their discretion over a 36-month period, providing financial flexibility to support its ongoing clinical development of VAL-083 for glioblastoma and REM-001 for cutaneous metastatic breast cancer. Kintara emphasizes that the agreement does not include penalties or warrants, and it retains the right to terminate without cost. The company anticipates using proceeds for working capital and development expenses.
Kintara Therapeutics (Nasdaq: KTRA) announced that President and CEO Robert E. Hoffman will present a corporate overview at the virtual Alliance Global Partners Summer Healthcare Conference on June 21-22, 2022. The company is focused on developing innovative cancer therapies, including VAL-083 for Glioblastoma and REM-001 for Cutaneous Metastatic Breast Cancer. Kintara aims to address unmet medical needs with its late-stage therapeutic programs. The company is also advancing clinical trials with promising efficacy and safety profiles for its treatments.
Kintara Therapeutics (Nasdaq: KTRA) announced that the FDA has granted Fast Track Designation to its candidate VAL-083 for treating newly-diagnosed unmethylated glioblastoma (GBM). This designation expedites the development and review process for drugs addressing serious conditions. Key benefits include enhanced FDA communication, eligibility for Accelerated Approval, and a 'rolling review' process. Kintara anticipates announcing top-line data from its GBM AGILE Study by the end of 2023, aiming for a swift commercial launch if VAL-083 is approved.
Kintara Therapeutics (Nasdaq: KTRA) announced that President and CEO Robert E. Hoffman will present a corporate overview at the JMP Securities Life Sciences Conference on June 16, 2022, at 11:30am ET. The conference will be held at the Lotte New York Palace Hotel. A live webcast will be available at this link, with a replay accessible for 30 days post-presentation. Kintara is developing innovative cancer therapies, including VAL-083 for Glioblastoma Multiforme and REM-001 for Cutaneous Metastatic Breast Cancer.
Kintara Therapeutics (KTRA) has received a 180-day extension from Nasdaq to meet the minimum bid price requirement of $1.00 per share. The deadline is now November 28, 2022. This extension follows KTRA’s previous notification on December 3, 2021, regarding non-compliance for 30 consecutive trading days. If KTRA's stock closes at or above $1.00 for ten consecutive business days, compliance will be confirmed. Failure to meet this requirement could lead to delisting, although KTRA may appeal such a decision.
Kintara Therapeutics (Nasdaq: KTRA) announced the activation of its first European site at University Hospital Zurich for the VAL-083 treatment arm in the GBM AGILE Phase 2/3 clinical trial for glioblastoma. This trial is currently underway at 44 sites in the U.S. and Canada, aiming to enroll 150-200 patients. The GBM AGILE study is designed to rapidly identify effective therapies through a seamless Phase 2/3 design, enhancing the potential for expedited FDA approvals. Kintara's VAL-083 demonstrates significant clinical activity against various solid tumors.